CN112386520A - Mesoderm injection composition for comprehensively improving skin color and preparation method thereof - Google Patents
Mesoderm injection composition for comprehensively improving skin color and preparation method thereof Download PDFInfo
- Publication number
- CN112386520A CN112386520A CN202011329887.0A CN202011329887A CN112386520A CN 112386520 A CN112386520 A CN 112386520A CN 202011329887 A CN202011329887 A CN 202011329887A CN 112386520 A CN112386520 A CN 112386520A
- Authority
- CN
- China
- Prior art keywords
- composition
- vitamin
- mesoderm
- components
- skin color
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 210000003716 mesoderm Anatomy 0.000 title claims abstract description 26
- 238000002347 injection Methods 0.000 title claims abstract description 21
- 239000007924 injection Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 239000000049 pigment Substances 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 229930003231 vitamin Natural products 0.000 claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 claims abstract description 13
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 13
- 239000008367 deionised water Substances 0.000 claims abstract description 11
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 11
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 11
- 239000000376 reactant Substances 0.000 claims abstract description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- 230000008439 repair process Effects 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- 229960003121 arginine Drugs 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 6
- 229960000401 tranexamic acid Drugs 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims description 3
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 claims description 3
- SCAKQYSGEIHPLV-IUCAKERBSA-N (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SCAKQYSGEIHPLV-IUCAKERBSA-N 0.000 claims description 3
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 claims description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 3
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- 108010087806 Carnosine Proteins 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 3
- 229930010555 Inosine Natural products 0.000 claims description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 241000237536 Mytilus edulis Species 0.000 claims description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003571 Vitamin B5 Natural products 0.000 claims description 3
- 229930003756 Vitamin B7 Natural products 0.000 claims description 3
- 229930003761 Vitamin B9 Natural products 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 229960002648 alanylglutamine Drugs 0.000 claims description 3
- 108010044940 alanylglutamine Proteins 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- 229940044199 carnosine Drugs 0.000 claims description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical group [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 229940108925 copper gluconate Drugs 0.000 claims description 3
- 229960003624 creatine Drugs 0.000 claims description 3
- 239000006046 creatine Substances 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 3
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims description 3
- 229940093497 ergothioneine Drugs 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 3
- 229910003472 fullerene Inorganic materials 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002591 hydroxyproline Drugs 0.000 claims description 3
- 229960003786 inosine Drugs 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 229960001983 magnesium aspartate Drugs 0.000 claims description 3
- CRSJYWPXKKSOCQ-CBAPHJFVSA-L magnesium;(2s)-2-aminobutanedioate;hydron;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O CRSJYWPXKKSOCQ-CBAPHJFVSA-L 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000020638 mussel Nutrition 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 239000011675 vitamin B5 Substances 0.000 claims description 3
- 235000009492 vitamin B5 Nutrition 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- 235000019159 vitamin B9 Nutrition 0.000 claims description 3
- 239000011727 vitamin B9 Substances 0.000 claims description 3
- -1 vitamin C glucoside Chemical class 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 51
- 210000002615 epidermis Anatomy 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 5
- 210000004207 dermis Anatomy 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 239000003086 colorant Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 229960003646 lysine Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000037072 sun protection Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a mesoderm injection composition for comprehensively improving skin color and a preparation method thereof, wherein the mesoderm injection composition is prepared from the following components in percentage by mass: 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repairing agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water, wherein the sum of the mass percentages of the components is 100%; the invention analyzes various factors influencing skin complexion, designs a composition capable of being used for mesoderm from epidermis to dermis layer mechanism, and the composition is sterilized by a terminal, is convenient and safe for doctors to use, and can comprehensively improve the problems of dull complexion, various color spots, aging and the like.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a mesoderm injection composition for comprehensively improving skin color and a preparation method of the composition.
Background
The basic color of the skin is formed by mixing three basic pigments of melanin, heme and carotene according to different proportions, the three primary colors of the skin are formed, the three primary colors of the skin are dynamically and three-dimensionally distributed on the living skin, and the colors of the three primary colors are superposed in different chromaticities to form the skin colors of different individuals of human beings. Among them, melanin is present in melanocytes in the basal layer of epidermis, is transferred to stratum corneum cells through melanocyte dendrites, then ascends to the stratum corneum along with epidermal cells, and is discharged out of the body along with exfoliation of aged keratinocytes. Under the irradiation of external environment such as ultraviolet rays, melanin is excessively synthesized and accumulated to the horny layer, so that the pigmented spot skin disease is formed, and simultaneously, the melanin metabolism is slow along with the increase of age, and the pigmented spot skin disease is also formed. Oxidized hemoglobin is present in the blood, making our skin ruddy, which is strongly related to the thickness of the epidermis and the skin barrier. Carotene is a reddish orange pigment, exists in the horny layer of the epidermis, enters the human body through food, enters blood from small intestines, is brought into the skin, cannot be manufactured by the human body, is taken by the outside, and is rarely researched in the field of skin diseases. In addition, non-enzymatic glycation reactions also known as maillard reactions occur in vivo, which are processes in which the aldehyde or ketone group of a reducing sugar reacts with free amino groups in proteins, lipids, or nucleic acid macromolecules in vivo or in vitro to form reversible or irreversible conjugates in the absence of enzymatic catalysis. Human skin tissues contain a large amount of collagen and elastin which are slowly metabolized and contain more lysine and hydroxylysine, and the collagen and the elastin can perform non-enzymatic saccharification reaction with free reducing sugar in the skin to form brown glycosylation products, so that the skin loses elasticity and is dark and lusterless. At the same time, the degree of hydration of the skin (mainly in combination with collagen, hyaluronic acid) has a significant influence on the skin colour by changing the refractive index of the light.
At present, skin color improving modes are various, such as skin external application or oral whitening and freckle removing products, the skin external application products cannot reach a basal layer and can not exert drug effect because of skin barrier obstruction, and the products are all a site aiming at melanin, so that the skin color is difficult to be comprehensively improved. The most used are also spot-removing of fruit acids and laser/intense pulsed light to improve skin color, but for fruit acids sensitive skin is not tolerant and after treatment serious color-sinking problems occur if sun protection is not in place. The laser and strong pulse light speckle removing recovery period is long, improper operation can cause skin burn, scar, pigment dehydration and other conditions, and more serious pigmentation can be easily caused if improper later-stage repair and sun protection are carried out.
The mesoderm (mesoderm) is located between the epidermis and the dermis layers. Mesoderm therapy is a mode of delivering drugs to mesoderm through a specific device, is firstly proposed by a French doctor Mackepite in 1952, and can fundamentally solve skin problems such as dark skin color, dryness, loose skin and the like.
At present, most of the mesoderm drugs for improving skin color are the combination of hyaluronic acid and vitamin C, tranexamic acid or glutathione and the like. The specific mechanism still relates to melanin, and the factors such as corium layer repair, saccharification reaction and the like are less considered, and the phenomenon of blackening can be caused due to poor postoperative protection, so that the ideal effect is difficult to achieve. And the compound is required to be compounded on site by a doctor when in use, the operation is complicated, and the risk of pollution also exists. Therefore, the development of a mesodermal composition which can comprehensively improve skin color and is convenient to operate is of great significance.
Disclosure of Invention
The invention aims to provide a mesoderm injection composition for comprehensively improving skin color, which solves the problems of slow penetration and absorption and slow effect of the existing smearing type product on one hand; on the other hand, the problem that the mesoderm product has a single action site aiming at the skin color problem, only the single factor of melanin is considered, and the operation complexity of a doctor is solved.
The second object of the present invention is to provide a process for the preparation of the above composition.
The invention adopts a first technical scheme that a mesoderm injection composition for comprehensively improving skin color is prepared from the following components in percentage by mass: 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repairing agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water, wherein the sum of the mass percentages of the components is 100%;
the moisturizing repair agent is at least 1 of hyaluronic acid, ectoin, glucan or mannitol;
the energy agent is at least 2 of adenosine, inosine, creatine, magnesium aspartate, zinc gluconate or copper gluconate;
the peptides are at least 2 combinations of oligopeptide-1, nonapeptide-1, lysine/arginine polypeptide, hexapeptide-2, tetrapeptide-4 or palmitoyl tripeptide-8;
the auxiliary material is the combination of sodium bisulfite and sodium hydroxide.
The first technical solution adopted by the present invention is further characterized in that,
the pigment inhibitor is at least one of tranexamic acid or nicotinamide.
The antioxidant is at least 3 of glutathione, vitamin C derivatives, ergothioneine or fullerene.
The vitamin C derivative is water-soluble vitamin C glucoside or vitamin C ethyl ether.
The vitamins are at least 2 of vitamin B5, vitamin B6, vitamin B7, vitamin B9 and vitamin B12.
The protein is at least 2 combinations of fibronectin, recombinant collagen, mussel albumin and whey protein.
The amino acid is at least 4 of lysine, histidine, arginine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, alanyl glutamine, cysteine, hydroxyproline, acetyl hydroxyproline or glutamine.
The anti-glycation reagent is carnosine.
The hyaluronic acid preferably has a molecular weight of 1400-1800KDa, 400-800KDa and 10KDa-50 KDa.
The second technical scheme adopted by the invention is as follows: a preparation method of a mesoderm injection composition for comprehensively improving skin color specifically comprises the following steps:
step 1, weighing 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repair agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water according to the mass percentage, wherein the sum of the mass percentages of the components is 100%;
step 2, adding the moisturizing repair agent, the pigment inhibitor and the energy agent into deionized water, heating to 85 ℃, preserving heat for 30min, and continuously stirring until the components are completely dissolved and transparent;
step 3, keeping the temperature at 85 ℃, sequentially adding an antioxidant, vitamins, peptides, amino acids, proteins, an anti-saccharification reactant and auxiliary materials, starting to cool and stir until the mixture is uniformly stirred, and fully dissolving the added components;
step 4, detecting the pH value of the composition in the step 3, and adjusting the pH value of the composition to 6.8-7.3 by using sodium hydroxide;
step 5, filling the components obtained in the step 4 into a high-temperature-resistant glass bottle, and carrying out damp-heat sterilization at the temperature of 115-121 ℃ for 15-30 min to obtain the composition;
and 6, detecting the composition in the step 5, wherein the pH value is 6.8-7.3, and the osmotic pressure is 270-350 mOsmol/L.
The invention has the beneficial effects that: the invention analyzes various factors influencing skin complexion, designs a composition capable of being used for mesoderm from epidermis to dermis layer mechanism, and the composition is sterilized by a terminal, is convenient and safe for doctors to use, and can comprehensively improve the problems of dull complexion, various color spots, aging and the like.
Detailed Description
The present invention will be described in detail with reference to specific examples.
The invention relates to a mesoderm injection composition for comprehensively improving skin color, which is prepared from the following components in percentage by mass: 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repairing agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water, wherein the sum of the mass percentages of the components is 100%.
The functions of the materials are as follows:
deionized water is used as a solvent.
The pigment inhibitor is at least one of tranexamic acid and nicotinamide, and mainly has the functions of inhibiting melanin synthesis and melanin transfer to stratum corneum.
The antioxidant is at least 3 of glutathione, vitamin C derivatives, ergothioneine or fullerene, and has the effects of scavenging free radicals, preventing excessive melanin generation, protecting cells from free radical damage, and reducing pigment, and especially, the vitamin C derivatives are preferably water soluble vitamin C glucoside and vitamin C ethyl ether.
The vitamins are at least 2 of vitamin B5, vitamin B6, vitamin B7, vitamin B9 or vitamin B12, and are mainly used for providing nutrient components.
The peptides are at least 2 combinations of oligopeptide-1, nonapeptide-1, lysine/arginine polypeptide, hexapeptide-2, tetrapeptide-4 or palmitoyl tripeptide-8, and have the main effects of regulating biological rhythm of skin, promoting collagen synthesis and strengthening skin.
The protein is at least 2 combinations of fibronectin, recombinant collagen, mussel albumin and whey protein, and has the main functions of providing structural substances for skin, promoting collagen synthesis and repair and increasing glossiness.
The amino acid is a combination of at least 4 of lysine, histidine, arginine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, alanyl glutamine, cysteine, hydroxyproline, acetyl hydroxyproline or glutamine, and mainly has the function of providing nutrient components.
The anti-glycation reactant is carnosine, and mainly has the effects of inhibiting the occurrence of glycation reaction, preventing the generation of brown glycosylation products and protecting collagen.
The moisturizing repair agent is at least 1 of hyaluronic acid, ectoin, glucan or mannitol, and mainly has the functions of providing moisture for the skin, repairing the skin and enabling the skin to be tender and glossy. In particular, hyaluronic acid preferably has a molecular weight of 1400-1800KDa, 400-800KDa and 10-50 KDa.
The energy agent is at least 2 of adenosine, inosine, creatine, magnesium aspartate, zinc gluconate or copper gluconate, and has the main function of providing energy for skin metabolism.
The auxiliary material is the combination of sodium bisulfite and sodium hydroxide, and the main function is that the sodium bisulfite ensures that the composition is stable in the period of validity and is not oxidized. And adjusting the pH of the product to 6.8-7.3 by using sodium hydroxide, wherein the pH is consistent with the pH of the mesoderm of the skin.
The invention relates to a preparation method of a mesoderm injection composition for comprehensively improving skin color, which comprises the following steps:
step 1, weighing 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repair agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water according to the mass percentage, wherein the sum of the mass percentages of the components is 100%.
And 2, adding the humectant, the pigment inhibitor and the energy agent into deionized water, heating to 85 ℃, keeping the temperature for 30min, and continuously stirring until the components are completely dissolved and transparent.
And 3, keeping the temperature at 85 ℃, sequentially adding an antioxidant, vitamins, peptides, amino acids, proteins, an anti-saccharification reactant and auxiliary materials, cooling and stirring until the mixture is uniformly stirred, and fully dissolving the added components.
And 4, detecting the pH value of the composition in the step 3, and adjusting the pH value of the composition to 6.8-7.3 by using sodium hydroxide.
And 5, filling the components obtained in the step 4 into a high-temperature-resistant glass bottle, and carrying out moist heat sterilization at the temperature of 115-121 ℃ for 15-30 min to obtain the composition.
And 6, detecting the composition in the step 5, wherein the pH value is 6.8-7.3, and the osmotic pressure is 270-350 mOsmol/L.
First, safety evaluation
1. Evaluation of cytotoxicity
Reference GB/T16886.5-2017 medical device biology evaluation part 5: in vitro cytotoxicity assay. The cytotoxicity grade evaluation of the samples 1 to 5 is carried out by adopting an MTT method, and the samples are specifically divided into five standards of 0, 1, 2, 3 and 4, and the corresponding reaction degree is five degrees of none, slight, mild, moderate and severe.
(1) Test protocol
The test uses the cell line L929 and the leaching medium is MEM culture medium containing 10% newborn bovine serum.
The experimental groups are the examples 1-5 of the invention, and the leaching mode is as follows: adding MEM culture solution at a ratio of 0.1g/ml under aseptic condition, leaching at 37 deg.C for 24 hr, and measuring; blank control is leaching medium without test sample, placed in the same vessel as the test sample during leaching, and subjected to the same conditions as the test sample; high density polyethylene was used as a negative control; phenol was used as a positive control. After the test object is incubated for 24h, the influence of the sample on the cell viability is determined by an MTT method, and the cytotoxicity response grade of the sample is judged. Each set was set to 6 replicates.
(2) Test results
The raw data were processed according to the relative increase ratio (RGR) ═ 100% of the mean absorbance of the test sample/the mean absorbance of the blank control, the results are shown in table 1:
table 1 examples 1-5 relative incremental ratios
The toxicity degree of examples 1 to 5 was evaluated according to Table 2, and the cytotoxicity of examples 2 and 5 was 0 grade, no cytotoxic reaction, and the cytotoxicity of examples 1, 3 and 4 was 1 grade, slight cytotoxicity.
TABLE 2 cytotoxic response grading Standard
From the data, the mesoderm composition for comprehensively improving the skin color has the cytotoxicity between 0 and 1 grade, has no toxicity or extremely slight reaction to cells, and has high safety.
2. Pyrogen evaluation
Pyrogen detection is carried out on the examples 1-5 according to the 1142 pyrogen detection method of the four general regulations of the pharmacopoeia of the people's republic of China 2015 edition, the specific detection method is that 3 rabbits are used in each example, within 15min after the normal body temperature is measured, a test solution (warmed to about 38 ℃) is slowly injected from the ear margin vein, 5 mL/patient is dosed, then the body temperature is measured for 1 time every 30min and is measured for 6 times, the temperature rise of all the rabbits is calculated, the total body temperature rise of all the rabbits is lower than 0.6 ℃, the total body temperature rise of 3 rabbits in each example is lower than 1.3 ℃, and the judgment is carried out according to the 1142 standards of the four general regulations of the 2015 edition of the pharmacopoeia of the people's republic of China, and the regulations are met. The composition of the invention has higher injection safety.
Second, evaluation of effectiveness
30 volunteers, 25 females and 5 males between the ages of 20-55 were selected. Wherein 10 people with dark skin color have facial features of dark, dry and lusterless skin color; 20 patients with mild and moderate color spots. 30 volunteers were randomly divided into 5 groups, and the inventive compositions of examples 1-5 were injected with 5ml per face and injection depth of 0.8-1.2mm using a demanga 2 generation water light injection apparatus (nine needles), respectively. Before injection, VISA is shot by washing the face, a layer of anesthetic paste is applied to the face, the anesthetic paste is removed after 30min, and the composition of the invention in the embodiment is injected in a sterile operation. After injection, the refrigerated sterile mechanical size face mask is applied for 20 min.
Observation indexes are as follows: the skin color improvement is divided into five grades: obviously improved, not obviously improved, obviously worsened and obviously worsened. The products were classified into four grades according to the comfort of injection: very satisfactory, general, and unsatisfactory.
Two weeks later, the VISA was photographed by washing the face and the results are shown in table 3 comparing the improvement in skin tone with the previous VISA photograph. Meanwhile, volunteers perform self-evaluation according to two aspects of skin color improvement and comfort, and the evaluation results are shown in table 4.
TABLE 3 VISA photographs of skin tone improvement results
TABLE 4 volunteer self-evaluation
As can be seen from tables 3 and 4, the effective rate of the composition of the present invention for improving skin color is more than 90%, the satisfaction in terms of comfort is 93%, and 30 people have no adverse reaction related to products, and have good safety.
Example (b):
at present, most of mesoderm skin color improving medicines are single combination of hyaluronic acid, vitamin C, tranexamic acid or glutathione and the like, and are compounded before doctors use, so that the risk of pollution exists. From the aspect of action mechanism and melanin, factors such as corium layer repair and saccharification reaction are less considered, the invention not only relates to a melanin formation mechanism, but also relates to the influence of the saccharification reaction on skin color, and simultaneously also relates to the influence of the corium layer repair on skin color, three dimension matching components are repaired from the melanin, the saccharification reaction and the corium layer, and the components are combined together to be directly used by a doctor without field configuration. The traditional mesoderm medicine, vitamin C, tranexamic acid and glutathione are combined together, meanwhile, nicotinamide, a plurality of antioxidants and polypeptide protein substances are added, the skin color problems such as color spots and the like can be comprehensively and efficiently improved from a corium layer to a cuticle layer, from melanin to saccharification and then to collagen, and meanwhile, the problem of postoperative blackening can be prevented.
Claims (10)
1. The mesoderm injection composition for comprehensively improving the complexion is characterized by being prepared from the following components in percentage by mass: 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repairing agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water, wherein the sum of the mass percentages of the components is 100%;
the moisturizing repair agent is at least 1 of hyaluronic acid, ectoin, glucan or mannitol;
the energy agent is at least 2 of adenosine, inosine, creatine, magnesium aspartate, zinc gluconate or copper gluconate;
the peptides are at least 2 combinations of oligopeptide-1, nonapeptide-1, lysine/arginine polypeptide, hexapeptide-2, tetrapeptide-4 or palmitoyl tripeptide-8;
the auxiliary material is the combination of sodium bisulfite and sodium hydroxide.
2. The injected mesodermal composition for improving overall skin tone of claim 1, wherein the pigment inhibitor is at least one of tranexamic acid or niacinamide.
3. The injected mesodermal composition for improving overall skin tone as claimed in claim 1, wherein said antioxidant is at least 3 of glutathione, vitamin C derivatives, ergothioneine or fullerene.
4. The mesodermal injection composition for providing overall improvement in skin tone of claim 3, wherein the vitamin C derivative is a water soluble vitamin C glucoside or vitamin C ethyl ether.
5. The injected mesoderm composition for improving overall skin tone as claimed in claim 1, wherein said vitamin is a combination of at least 2 of vitamin B5, vitamin B6, vitamin B7, vitamin B9 and vitamin B12.
6. The injected mesodermal composition for improving overall skin color of claim 1, wherein the protein is at least 2 of fibronectin, recombinant collagen, mussel albumin, whey protein.
7. The mesodermal injection composition for improving overall skin color of claim 1, wherein the amino acid is a combination of at least 4 of lysine, histidine, arginine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, alanylglutamine, cysteine, hydroxyproline, acetylhydroxyproline, or glutamine.
8. The injected mesodermal composition for improving overall skin tone of claim 1, wherein the anti-glycation reagent is carnosine.
9. The mesoderm injection composition for improving skin color comprehensively as claimed in claim 1, wherein said hyaluronic acid is preferably selected from the group consisting of 1800kDa, 400 kDa, 800kDa and 10kDa-50 kDa.
10. A preparation method of a mesoderm injection composition for comprehensively improving skin color is characterized by comprising the following steps:
step 1, weighing 1-2.5% of pigment inhibitor, 1-2% of antioxidant, 0.08-0.6% of vitamin, 0.6-1.8% of peptide, 0.6-1.7% of protein, 0.3-0.7% of amino acid, 0.1-0.3% of anti-saccharification reactant, 0.6-0.7% of moisturizing repair agent, 0.2-0.6% of energy agent, 0.1-0.3% of auxiliary material and the balance of deionized water according to the mass percentage, wherein the sum of the mass percentages of the components is 100%;
step 2, adding the humectant, the pigment inhibitor and the energy agent into deionized water, heating to 85 ℃, keeping the temperature for 30min, and continuously stirring until the components are completely dissolved and transparent;
step 3, keeping the temperature at 85 ℃, sequentially adding an antioxidant, vitamins, peptides, amino acids, proteins, an anti-saccharification reactant and auxiliary materials into the composition obtained in the step 1, cooling and stirring until the mixture is uniformly stirred, and fully dissolving the added components;
step 4, detecting the pH value of the composition in the step 3, and adjusting the pH value of the composition to 6.8-7.3 by using sodium hydroxide;
step 5, filling the components obtained in the step 4 into a high-temperature-resistant glass bottle, and carrying out damp-heat sterilization at the temperature of 115-121 ℃ for 15-30 min to obtain the composition;
and 6, detecting the composition in the step 5, wherein the pH value is 6.8-7.3, and the osmotic pressure is 270-350 mOsmol/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011329887.0A CN112386520A (en) | 2020-11-24 | 2020-11-24 | Mesoderm injection composition for comprehensively improving skin color and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011329887.0A CN112386520A (en) | 2020-11-24 | 2020-11-24 | Mesoderm injection composition for comprehensively improving skin color and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112386520A true CN112386520A (en) | 2021-02-23 |
Family
ID=74607682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011329887.0A Pending CN112386520A (en) | 2020-11-24 | 2020-11-24 | Mesoderm injection composition for comprehensively improving skin color and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112386520A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114225007A (en) * | 2021-11-09 | 2022-03-25 | 西安润玉医疗科技有限公司 | Whey protein spray for repairing superficial wound and preparation method thereof |
| CN117815135A (en) * | 2024-01-03 | 2024-04-05 | 华泽睿孚生物技术(广州)有限公司 | Whitening and freckle-removing composition containing North American arbor bark extract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375005A (en) * | 2017-08-07 | 2017-11-24 | 深圳市维琪医药研发有限公司 | A kind of antioxidation and peptide composition and its application for suppressing B16 cell |
| CN110237229A (en) * | 2019-07-31 | 2019-09-17 | 孟雨 | A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree |
| CN111297727A (en) * | 2019-12-25 | 2020-06-19 | 华熙生物科技股份有限公司 | Beautifying and plasticizing treatment composition and application thereof |
-
2020
- 2020-11-24 CN CN202011329887.0A patent/CN112386520A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375005A (en) * | 2017-08-07 | 2017-11-24 | 深圳市维琪医药研发有限公司 | A kind of antioxidation and peptide composition and its application for suppressing B16 cell |
| CN110237229A (en) * | 2019-07-31 | 2019-09-17 | 孟雨 | A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree |
| CN111297727A (en) * | 2019-12-25 | 2020-06-19 | 华熙生物科技股份有限公司 | Beautifying and plasticizing treatment composition and application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114225007A (en) * | 2021-11-09 | 2022-03-25 | 西安润玉医疗科技有限公司 | Whey protein spray for repairing superficial wound and preparation method thereof |
| CN114225007B (en) * | 2021-11-09 | 2023-08-25 | 西安润玉医疗科技有限公司 | Whey protein spray for repairing superficial wound surface and preparation method thereof |
| CN117815135A (en) * | 2024-01-03 | 2024-04-05 | 华泽睿孚生物技术(广州)有限公司 | Whitening and freckle-removing composition containing North American arbor bark extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnamachari | Some aspects of copper metabolism in pellagra | |
| US20110160137A1 (en) | Composition containing collagen peptide for improving skin care | |
| CN109998938A (en) | A kind of peptide composition for the light spot of whitening skin lightening | |
| KR20080030023A (en) | Wrinkle-preventive/ameliorating agent | |
| CN112386520A (en) | Mesoderm injection composition for comprehensively improving skin color and preparation method thereof | |
| CN110037952A (en) | A kind of crease-resistant and Vitamin K eye mask patch | |
| CN111035609A (en) | Micromolecular polypeptide eye essence and preparation method thereof | |
| CN111000770A (en) | Whitening cream containing pearl peptide | |
| EP1493431A3 (en) | Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions | |
| CN111888279B (en) | Method for promoting collagen production and corresponding medicine or cosmetic | |
| JPH09291011A (en) | Composition suitable for eternal use | |
| CN111557863B (en) | Application of composition containing hyaluronic acid and polyalcohol in improving skin permeability of water-soluble vitamin | |
| CN111588652B (en) | Composition containing hyaluronic acid and polyalcohol and application thereof | |
| JP2000309521A (en) | Skin lotion | |
| CN114317661B (en) | Method for preparing multiple active collagen | |
| JP7448642B2 (en) | Compositions and their use in the preparation of products for the care of the skin of night owls | |
| KR101305274B1 (en) | Composition for improving collagen synthesis | |
| KR101218898B1 (en) | Composition for improving collagen synthesis | |
| KR20150039343A (en) | Cosmetic composition comprising stem cell medium for improving skin state | |
| JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
| CN111961119B (en) | Application of polypeptide in preparation of medicine or cosmetic for promoting collagen secretion | |
| JP3507635B2 (en) | Composition suitable for external use | |
| CN100562306C (en) | Contain the biological beauty skin care item of body keratinized cell growth factor-2 and the preparation method of recombinant human keratinized cell growth factor-2 | |
| JPH06279294A (en) | Collagen synthesis promoter | |
| CN113545998B (en) | Hydroxyapatite and collagen composition and application thereof in removing nevus, removing freckles, reducing pigmentation and whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210223 |